Helix BioPharma (TSE:HBP) Shares Cross Below 50 Day Moving Average – Should You Sell?

Helix BioPharma Corp. (TSE:HBP) passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$1.52 and traded as low as C$1.40. Helix BioPharma shares last traded at C$1.40, with a volume of 308 shares traded.

Helix BioPharma Stock Down 1.4%

The company has a debt-to-equity ratio of 2.44, a quick ratio of 1.03 and a current ratio of 0.45. The stock has a market cap of C$106.93 million, a price-to-earnings ratio of -35.00 and a beta of 0.43. The firm’s 50-day simple moving average is C$1.52 and its two-hundred day simple moving average is C$1.82.

Helix BioPharma (TSE:HBP) last announced its earnings results on Friday, June 12th. The biopharmaceutical company reported C($0.01) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that Helix BioPharma Corp. will post -0.11 EPS for the current fiscal year.

Helix BioPharma Company Profile

Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker¿ L-DOS47, a clinical-stage antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy and augment the effectiveness of today’s front-running anti-cancer treatments. L-DOS47 has completed Phase Ib studies in non-small cell lung cancer (NSCLC) and shares its CEACAM6-targeting foundation with Helix’s next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery.